Lineage Cell Therapeutics
LCTX
LCTX
96 hedge funds and large institutions have $161M invested in Lineage Cell Therapeutics in 2017 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 39 increasing their positions, 18 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
3.43% more ownership
Funds ownership: 44.75% → 48.18% (+3.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
97% less call options, than puts
Call options by funds: $3K | Put options by funds: $103K
Holders
96
Holding in Top 10
1
Calls
$3K
Puts
$103K
Top Buyers
| 1 | +$16.9M | |
| 2 | +$7.67M | |
| 3 | +$6.39M | |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.21M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.43M |
Top Sellers
| 1 | -$379K | |
| 2 | -$283K | |
| 3 | -$239K | |
| 4 |
Citigroup
New York
|
-$224K |
| 5 |
Morgan Stanley
New York
|
-$210K |